Evidence map›Paper›PMID 33844154›Full record

ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2021

Repetitive Transcranial Magnetic Stimulation as a Therapeutic and Probe in Schizophrenia: Examining the Role of Neuroimaging and Future Directions.

Stephen J Brandt, Halimah Y Oral, Carla Arellano-Bravo, Martin H Plawecki, Tom A Hummer, Michael M Francis

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Early efficacy of rTMS intervention at week 2 predicts subsequent responses at week 24 in schizophrenia in a randomized controlled trial.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Neuroimaging Advances in Neurologic and Neurodegenerative Diseases.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Stephen J BrandtIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA.
Halimah Y OralIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA.
Carla Arellano-BravoIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA.
Martin H PlaweckiIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA.
Tom A HummerIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA.
Michael M FrancisIndiana University School of Medicine, Department of Psychiatry, 355W 16 St., Indianapolis, IN, USA. mmfranci@iupui.edu.ORCID http://orcid.org/0000-0002-9287-8544
Indiana University School of Medicine

Funding

Repetitive Transcranial Magnetic Stimulation as a Probe of Episodic Memory Neurocircuitry in SchizophreniaR21MH119564 · NIMH · INDIANA UNIVERSITY INDIANAPOLIS · PI FRANCIS, MICHAEL M · 2019 to 2020
$436k
NIMH NIH HHS R21 MH119564
6 · The paper itself

Abstract

Schizophrenia is a complex condition associated with perceptual disturbances, decreased motivation and affect, and disrupted cognition. Individuals living with schizophrenia may experience myriad poor outcomes, including impairment in independent living and function as well as decreased life expectancy. Though existing treatments may offer benefit, many individuals still experience treatment resistant and disabling symptoms. In light of the negative outcomes associated with schizophrenia and the limitations in currently available treatments, there is a significant need for novel therapeutic interventions. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive brain stimulation technique that can modulate the activity of discrete cortical regions, allowing direct manipulation of local brain activation and indirect manipulation of the target's associated neural networks. rTMS has been studied in schizophrenia for the treatment of auditory hallucinations, negative symptoms, and cognitive deficits, with mixed results. The field's inability to arrive at a consensus on the use rTMS in schizophrenia has stemmed from a variety of issues, perhaps most notably the significant heterogeneity amongst existing trials. In addition, it is likely that factors specific to schizophrenia, rather than the rTMS itself, have presented barriers to the interpretation of existing results. However, advances in approaches to rTMS as a biologic probe and therapeutic, many of which include the integration of neuroimaging with rTMS, offer hope that this technology may still play a role in improving the understanding and treatment of schizophrenia.

Indexed as

BrainForecastingHumansNeuroimagingNeuronavigationSchizophreniaTranscranial Magnetic StimulationTreatment OutcomefMRIMRIRepetitive transcranial magnetic stimulationSchizophrenia

Identifiers

PMID33844154
PMCPMC8423934
OpenAlexW3155097483

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.